AMACR (α-Methylacyl-CoA Racemase) Expression as a Prognostic Tissue Marker in Prostatic Adenocarcinoma Sub-Saharan Experience

Ahmed Ibn Edriss Mohamed1, El Jaily Mohamed2 and Mohamed El Imam Mohamed2*

1Department of Medicine, University of El Imam EL Mahdi, Sudan
2Department of Medicine, University of Gezira, Sudan

^*Correspondance to: Mohamed El Imam Mohamed 

 PDF  Full Text DOI: 10.25107/2474-1647.2796

Abstract

Background and Objective: Prostate cancer is the most common cancer. Histologically 95% of prostatic cancers are adenocarcinomas. Numerous studies focused on the role of AMACR immunohistochemical expression as diagnostic marker for prostate cancer, few of them investigate the role of AMACR as prognostic marker. This study aimed to evaluate AMACR immunohistochemical expression patterns as prognostic marker for prostate cancer. Method: A 100 prostate needle biopsies during 2017-2019, confirmed as adenocarcinomas by experienced histopathologist by using Hematoxylin and Eosin (H&E) stain are selected. Prostatic adenocarcinomas were graded according to the 2014 ISUP/WHO Gleason grading. Sections of 5 μm thickness were cut, then Immunohistochemistry (IHC) was performed using monoclonal AMACR antibodies and the results were analyzed using SPSS. Results: 89 (89%) of prostatic adenocarcinoma cases showed AMACR proportion score +3 staining (more than 50% cells were stained), 5 (5%) proportion score +2, 1 (1%) proportion score +1 and 5 (5%) proportion score 0. No statistical significant correlation between AMACR positivity and Gleason’s score grade group (P value = 0.474). The study concluded that AMACR expression doesn’t depend on tumor differentiation.

Keywords

Prostate Cancer; Gleason’s Score; AMACR; Sudan

Cite the article

Ibn Edriss Mohamed A, Mohamed EJ, El Imam Mohamed M. AMACR (α-Methylacyl-CoA Racemase) Expression as a Prognostic Tissue Marker in Prostatic Adenocarcinoma Sub-Saharan Experience. Clin Surg. 2020; 5: 2796..